News

Phase 1 trial to open into SC291, CAR T-cell therapy for AAV

The U.S. Food and Drug Administration has approved Sana Biotechnology’s investigational new drug (IND) application requesting a Phase 1 clinical trial of its investigational cell therapy SC291 in people with ANCA-associated vasculitis (AAV) and other autoimmune diseases. “Our goal is to develop SC291 for patients with multiple…

AAV can lead to weak trunk muscles in very rare cases

In rare cases, ANCA-associated vasculitis (AAV) can result in muscle weakness that affects mainly the trunk and the muscles closest to the trunk due to blood vessel inflammation within the muscles, a study shows. Comprehensive tests of four AAV patients with this distinct clinical feature show that muscle symptoms…

Complement protein in blood may predict kidney damage in MPA

High blood levels of the immune protein C4 are significantly associated with greater kidney-specific disease activity and a higher chance of developing kidney failure with microscopic polyangiitis (MPA), the most common type of ANCA-associated vasculitis (AAV), a study shows. For this reason, measuring blood C4 levels may help predict…

Severity of anemia tied to specific kidney lesions in AAV patients

The severity of anemia, or low levels of oxygen-carrying hemoglobin, is significantly associated with certain kidney lesions in people with ANCA-associated vasculitis (AAV) and kidney involvement, a study showed. These findings “reflect an additional aspect of anemia pathophysiology [disease mechanisms] in ANCA-associated renal vasculitis,” the researchers wrote. The study,…

GPA is most common type of ANCA-associated vasculitis in Italy

Granulomatosis with polyangiitis (GPA) is the most common type of ANCA-associated vasculitis (AAV) in Italy and is linked to worse symptoms and higher mortality and healthcare costs than microscopic polyangiitis (MPA), another common AAV type, a study finds. Using immunosuppressive glucocorticoids was also associated with higher costs…

Rituximab found as effective for AAV survival as cyclophosphamide

Treatment with rituximab has a similar efficacy to cyclophosphamide — both of them standard immunosuppressive therapies — in reducing short-time mortality in adults with life-threatening ANCA-associated vasculitis (AAV), a study in Japan found. Moreover, rituximab was associated with a significantly lower risk of fungal infections relative to cyclophosphamide. However,…

Low-dose glucocorticoids just as effective for long-term AAV control

A treatment regimen that combines low-dose glucocorticoids and rituximab is just as effective at controlling ANCA-associated vasculitis (AAV) as a standard regimen of high-dose glucocorticoids and rituximab, according to two-year data from a clinical trial. The long-term findings indicate that, while the efficacy is comparable, the risk of serious…